Clindamycin Injection IP

Description

CLIVAX-600 is a high-quality Clindamycin Injection IP that is offered by Pharvax Biosciences. Pharvax is a WHO-GMP pharmaceutical company with its corporate office located at Panchkula (Haryana). Recommended by hospitals, nursing homes and clinicians across India, this Clindamycin Injection IP is an ISO-certified fast-acting broad-spectrum lincosamide antibiotic that is made from good-quality Clindamycin Phosphate. 

Due to its broad spectrum and reliable high-quality manufacturing standards, it is a prominent injection used for the treatment of complex anaerobic and some specific Gram-positive infections and diseases. 

The company is enjoying wide acceptance in the Indian market because of the quality being offered and a booming countrywide distributor/stockist network. Clindamycin Injection in the Antibiotic Segment” is available for PCD pharma franchise partners and distributors.

What is CLIVAX-600?

Clindamycin phosphate is a semi-synthetic antibiotic derived from lincomycin, which is administered as a sterile solution for injection (IM, IV) under the guidance and supervision of a physician. Clindamycin inhibits bacterial protein synthesis and thus prevents the multiplication of bacteria by preventing the formation of the next amino acid of the strands. CLIVAX-600 is preferred in hospitals because of its penetration to tissues, within 15 minutes of injection, even to highly infected tissues, such as in the cavities of abscesses.

Key Therapeutic Uses of Clindamycin Injection

• Serious skin and soft tissue infections, including cellulitis and abscesses
• Bone and joint infections, such as osteomyelitis and septic arthritis
• Intra-abdominal infections caused by anaerobic bacteria
• Gynaecological infections, including endometritis and pelvic inflammatory disease
• Lower respiratory tract infections such as empyema, lung abscess, and pneumonia
• Septicaemia caused by susceptible staphylococci, streptococci, and pneumococci
• As part of surgical prophylaxis in patients allergic to penicillin

Mechanism of Action

Clindamycin binds to the 50S ribosomal subunit in susceptible bacteria and blocks the very initiation of peptide chain formation, so protein synthesis is suppressed. Because its action is mainly bacteriostatic, though at higher concentrations it can become bactericidal. Clindamycin Injection is effective against a broad range of anaerobic organisms and gram-positive aerobes. It also covers many strains that are resistant to other antibiotic classes, kind of as a practical workaround in real infections. Another point is how well it can reach bone tissue, synovial fluid, and those abscess pockets, which gives it an obvious clinical edge compared with several alternative options.

Dosage and Administration  

CLIVAX-600 is meant for use only under the oversight of a qualified medical practitioner, most often in a hospital or clinic. The exact dosage, timing, and how it is given (either deep intramuscular or via slow intravenous infusion) are set by the treating physician. This decision usually depends on the severity of the infection, the patient’s body weight, renal and hepatic function, and how the patient is responding clinically. It is critical to follow a strict aseptic injection technique and to stick to the recommended dilution protocols, because that helps protect the patient and also supports therapeutic effectiveness.

Safety Profile and  Precautions

As with all antibiotic therapy, Clindamycin Injection should be used with caution in patients with a history of gastrointestinal disease, hepatic impairment, or known hypersensitivity to lincosamides. Clostridioides difficile-associated diarrhoea has been reported with clindamycin use, as with most antibiotics, and should be considered in patients presenting with diarrhoea during or after treatment. CLIVAX-600 should not be administered rapidly via intravenous push and must always be diluted and infused as per standard clinical protocol. Patients should be monitored for hypersensitivity reactions, and the product should be avoided in those with known allergy to clindamycin or lincomycin.

Note: The above content is for informational purposes and does not guarantee anything. Therefore, inform your doctor before using Clindamycin Injection IP 

Why Choose CLIVAX-600 from Pharvax Biosciences?

• Manufactured in a WHO-GMP and ISO-certified facility
• Strict batch-to-batch quality testing for purity and sterility
• Stable formulation with reliable shelf life and cold-chain-friendly packaging
• Backed by complete documentation, COA, and regulatory support for franchise partners
• Competitive pricing with attractive monopoly-based franchise margins
• Promotional and marketing support, including visual aids, MR bags, and product literature

Clindamycin Injection IP PCD Pharma Franchise

Looking for a Clindamycin Injection IP PCD Pharma Franchise with monopoly rights, genuine quality, and strong field support? Pharvax Biosciences welcomes franchise enquiries from across India for Clindamycin Injection IP PCD Pharma Franchise, offering low-investment, high-growth business opportunities for pharma professionals nationwide.